Stock Events

Stock Events

Dogwood Therapeutics 

$2.18
0
+$0.32+17.2% Thursday 04:00

Statistics

Day High
2.18
Day Low
2.18
52W High
-
52W Low
-
Volume
602
Avg. Volume
-
Mkt Cap
5M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-8.2
-5.53
-2.86
-0.19
Expected EPS
-0.193333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-25.73MNet Income

Analyst Ratings

$12.00Average Price Target
The highest estimate is 12.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DWTX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences focuses on antiviral drugs, directly competing with Virios in the antiviral space.
Merck
MRK
Mkt Cap214.76B
Merck & Co. develops treatments for infectious diseases, including antivirals, making it a direct competitor.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a strong portfolio in antiviral drugs, competing in the same market as Virios.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a significant presence in the antiviral drug market, making it a competitor to Virios.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops and markets antiviral medications, positioning it as a competitor to Virios.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb offers antiviral drugs, competing with Virios in the pharmaceutical market.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division, competes in the antiviral space with Virios.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in the development of antiviral treatments, making it a competitor.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals focuses on infectious diseases, including antivirals, competing with Virios.
Novartis
NVS
Mkt Cap237.61B
Novartis AG has a diverse portfolio that includes antiviral drugs, competing with Virios in the pharmaceutical market.

About

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Show more...
CEO
ISIN
US92829J2033

Listings

XNAS
US
DWTX
BOATS
BOATS
DWTX.BOATS

0 Comments

Share your thoughts

FAQ

What is Dogwood Therapeutics stock price today?▼
The current price of DWTX.BOATS is $2.18 USD — it has increased by +17.2% in the past 24 hours. Watch Dogwood Therapeutics stock price performance more closely on the chart.
What is Dogwood Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Dogwood Therapeutics stocks are traded under the ticker DWTX.BOATS.
What is Dogwood Therapeutics market cap?▼
Today Dogwood Therapeutics has the market capitalization of 5M
When is the next Dogwood Therapeutics earnings date?▼
Dogwood Therapeutics is going to release the next earnings report on May 07, 2026.
What were Dogwood Therapeutics earnings last quarter?▼
DWTX.BOATS earnings for the last quarter are -0.26 USD per share, whereas the estimation was -0.86 USD resulting in a +69.77% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Dogwood Therapeutics revenue for the last year?▼
Dogwood Therapeutics revenue for the last year amounts to 0 USD.
What is Dogwood Therapeutics net income for the last year?▼
DWTX.BOATS net income for the last year is -25.73M USD.
When did Dogwood Therapeutics complete a stock split?▼
Dogwood Therapeutics has not had any recent stock splits.